HSCS
HeartSciences Inc. Common Stock
stock NASDAQ

Do you have proof
Here are my notes: 
Despite significant budget and staffing cuts imposed by the Department of Government Efficiency (DOGE), the FDA continues to advance its regulatory mission, recently approving several important therapies and devices:
March 2025 FDA Approvals:
• Encelto (allogeneic gene therapy): Approved March 7, for idiopathic macular telangiectasia type 2 (MacTel).
• Omlyclo (omalizumab-igec): Approved March 7, for asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergies, and urticaria.
• Generic Xarelto (rivaroxaban): First generics approved March 4, for cardiovascular indications in CAD/PAD.
• Tislelizumab plus Chemotherapy: Approved March 2025, for patients with certain advanced cancers.
• SPN-830 (Onapgo): Supernus Pharmaceuticals’ infusion device for Parkinson’s disease approved March 2025.
• FUROSCIX®: scPharmaceuticals’ treatment for edema in chronic kidney disease approved March 2025.
$ICCM The recent FDA clearance of ReWalk's exoskeleton (LFWD) via the 510(k) process is a favorable signal for IceCure Medical, reinforcing confidence in ICCM's anticipated FDA approval for ProSense in the very near term.
HeartSciences (HSCS) Catalyst Update
• Ticker: HSCS
• Device: MyoVista
• Indication: Heart Disease
• Stage: Pre-submission
• Previous Decision Date: 31/12/25 ET
• New Decision Date: 30/06/25 ET (Moved ~6 months earlier)
Analysis & Investor Takeaway:
Despite recent DOGE-led cuts at the FDA, the agency’s pace of critical approvals continues

Do you have proof
Here are my notes: 
Despite significant budget and staffing cuts imposed by the Department of Government Efficiency (DOGE), the FDA continues to advance its regulatory mission, recently approving several important therapies and devices:
March 2025 FDA Approvals:
• Encelto (allogeneic gene therapy): Approved March 7, for idiopathic macular telangiectasia type 2 (MacTel).
• Omlyclo (omalizumab-igec): Approved March 7, for asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergies, and urticaria.
• Generic Xarelto (rivaroxaban): First generics approved March 4, for cardiovascular indications in CAD/PAD.
• Tislelizumab plus Chemotherapy: Approved March 2025, for patients with certain advanced cancers.
• SPN-830 (Onapgo): Supernus Pharmaceuticals’ infusion device for Parkinson’s disease approved March 2025.
• FUROSCIX®: scPharmaceuticals’ treatment for edema in chronic kidney disease approved March 2025.
$ICCM The recent FDA clearance of ReWalk's exoskeleton (LFWD) via the 510(k) process is a favorable signal for IceCure Medical, reinforcing confidence in ICCM's anticipated FDA approval for ProSense in the very near term.
HeartSciences (HSCS) Catalyst Update
• Ticker: HSCS
• Device: MyoVista
• Indication: Heart Disease
• Stage: Pre-submission
• Previous Decision Date: 31/12/25 ET
• New Decision Date: 30/06/25 ET (Moved ~6 months earlier)
Analysis & Investor Takeaway:
Despite recent DOGE-led cuts at the FDA, the agency’s pace of critical approvals continues